HIMS Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

38.588

Open

38.010

VWAP

36.97

Vol

12.21M

Mkt Cap

8.86B

Low

36.145

Amount

451.29M

EV/EBITDA(TTM)

75.63

Total Shares

231.46M

8.74B

EV/OCF(TTM)

31.19

P/S(TTM)

3.88

Hims & Hers Health, Inc. operates as a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products.

Events Timeline

(ET)

2026-06-30

11:00:00

Hims and Hers Health Shares Up 1.23% to $33.80

2026-06-26 (ET)

2026-06-26

12:00:00

Hims and Hers Health Shares Rise 5.3%

2026-06-18 (ET)

2026-06-18

17:00:00

Hims and Hers Health Shares Rise 11.49%

2026-06-15 (ET)

2026-06-15

15:00:00

Hims and Hers Health Shares Rise 10.7%

News

8.5

07-06stocktwits

PinnedHIMS CEO Emphasizes Long-Term Execution Amid Stock Volatility

8.5

02:04 AMNASDAQ.COM

Investment Choices: Hims & Hers vs. Teladoc

6.5

01:06 AMFool

Investment Comparison Between Hims & Hers and Teladoc

8.0

07-06NASDAQ.COM

United Therapeutics Corp Sees Surge in Options Trading Volume

8.5

07-02stocktwits

Hims & Hers Secures $400M Financing Agreement with JPMorgan Chase

8.5

07-01seekingalpha

FDA Revives Advisory Committee Meetings for Drug Approvals

12 Analyst Rating

Wall Street analysts forecast HIMS stock price to rise

3 Buy

6 Hold

3 Sell

Hold

Current: 0.000

Low

16.50

Averages

32.95

High

60.00

Current: 0.000

Low

16.50

Averages

32.95

High

60.00

BofA

Allen Lutz

Neutral

maintain

$25 -> $36

AI Analysis

2026-07-01

Reason

BofA

Allen Lutz

Price Target

$25 -> $36

AI Analysis

2026-07-01

maintain

Neutral

Reason

BofA analyst Allen Lutz raised the firm's price target on Hims & Hers to $36 from $25 and keeps a Neutral rating on the shares. Bloomberg Second Measure card data has improved in recent months, suggesting "solid early traction" for Hims' branded GLP-1 franchise, the analyst tells investors. However, while Hims' oral Wegovy launch is trending well, it is too early to tell if Hims can capture and retain enough GLP-1 subscribers to achieve the significant EBITDA ramp embedded in second half guidance, the analyst added.

Canaccord

Buy

maintain

$32 -> $40

2026-07-01

Reason

Canaccord

Price Target

$32 -> $40

2026-07-01

maintain

Buy

Reason

Canaccord raised the firm's price target on Hims & Hers to $40 from $32 and keeps a Buy rating on the shares. The firm said the company has been buoyed by improving CC data and growing enthusiasm around its peptide opportunity. Though the thesis around the latter took a step back earlier in the week when the FDA declined to propose seven of the peptides under review for the bulk compounding list ahead of its late-July advisory meeting, they are encouraged by the line-up of the committee advising on peptides of several new panelists whose appear constructive on peptides.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HIMS

Unlock Now

Valuation Metrics

The current forward P/E ratio for Hims & Hers Health Inc (HIMS.N) is 58.82, compared to its 5-year average forward P/E of 12.71. For a more detailed relative valuation and DCF analysis to assess Hims & Hers Health Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

12.71

Current PE

58.82

Overvalued PE

70.16

Undervalued PE

-44.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

13.12

Current EV/EBITDA

-33.16

Overvalued EV/EBITDA

46.37

Undervalued EV/EBITDA

-20.13

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.72

Current PS

1.91

Overvalued PS

3.99

Undervalued PS

1.44

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

stocks that will explode in next 30 days

Intellectia · 640 candidates

Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA5, PriceAboveMA20Month Price Change Pct: >= $0.00One Month Rise Prob: >= 70One Month Predict Return: >= 0.0%

Ticker

Name

Market Cap$

PRCH

Porch Group Inc

1.23B

ROMA

Roma Green Finance Ltd

396.70M

MCBS

Metrocity Bankshares Inc

921.13M

Under Armour Inc

2.59B

INNV

InnovAge Holding Corp

1.08B

DOCN

DigitalOcean Holdings Inc

15.94B

how to find fast rising U.S. stocks daily.

Intellectia · 37 candidates

Market Cap: >= 500.00MRegion: USPrice: $3.00 - $150.00Volume: >= 1,000,000Price Change Pct: >= $5.00List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

MXL

Maxlinear Inc

3.07B

POET

POET Technologies Inc

1.79B

OGN

Organon & Co

2.24B

INTC

Intel Corp

334.79B

INDI

indie Semiconductor Inc

777.25M

EOSE

Eos Energy Enterprises Inc

2.35B

Day trading stocks

Intellectia · 26 candidates

Region: USPrice: $5.00 - $80.00Price Change Pct: >= $5.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

GFS

GlobalFoundries Inc

32.26B

UMC

United Microelectronics Corp

31.75B

SIRI

Sirius XM Holdings Inc

9.16B

HIMS

Hims & Hers Health Inc

7.07B

LEGN

Legend Biotech Corp

4.64B

BlackBerry Ltd

3.23B

can you find one that is favorable

Intellectia · 63 candidates

Price: $5.00 - $50.00Volume: >= 1,000,000Rsi Category: moderate, overboughtPrice Change Pct: $3.00 - $15.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

SMR

Nuscale Power Corp

4.34B

HIMS

Hims & Hers Health Inc

6.57B

IONQ

IONQ Inc

16.90B

NCLH

Norwegian Cruise Line Holdings Ltd

9.56B

COMP

Compass Inc

6.07B

HTZ

Hertz Global Holdings Inc

2.34B

Any sector or business

Intellectia · 24 candidates

Market Cap: >= 1000.00MPrice: >= $5.00Price Change Pct: >= $5.00Monthly Average Dollar Volume: >= 1,000,000News Driver: Positive

Ticker

Name

Market Cap$

NextNav Inc

2.92B

NVTS

Navitas Semiconductor Corp

2.85B

SMMT

Summit Therapeutics Inc

18.95B

RUM

Rumble Inc

2.78B

IRDM

Iridium Communications Inc

4.59B

LUNR

Intuitive Machines Inc

5.91B

which stocks I focus for day trading

Intellectia · 47 candidates

Market Cap: >= 2.00BRegion: USPrice: $10.00 - $70.00Price Change Pct: $4.00 - $18.00Relative Vol: >= 1.80List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 3,000,000

Ticker

Name

Market Cap$

Planet Labs PBC

11.91B

SMMT

Summit Therapeutics Inc

16.39B

IRDM

Iridium Communications Inc

4.02B

LUNR

Intuitive Machines Inc

5.18B

SGML

Sigma Lithium Corp

2.03B

HIMS

Hims & Hers Health Inc

5.54B

What is a good stock for day trade today

Intellectia · 194 candidates

Market Cap: >= 500.00MPrice: $5.00 - $100.00Price Change Pct: $3.00 - $15.00Relative Vol: >= 2Beta: HighRiskList Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

INTC

Intel Corp

206.50B

ONDS

Ondas Inc

3.78B

Nu Holdings Ltd

65.60B

NIO

NIO Inc

13.68B

CDE

Coeur Mining, Inc

10.59B

Unity Software Inc

8.96B

list top 10 stocks with bullish momentum

Intellectia · 88 candidates

Market Cap: >= 2.00BRegion: USRsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Month Price Change Pct: >= $10.00

Ticker

Name

Market Cap$

AAOI

Applied Optoelectronics Inc

8.89B

Babcock & Wilcox Enterprises Inc

2.11B

AHG

Akso Health Group

2.03B

AMPX

Amprius Technologies Inc

2.46B

DNTH

Dianthus Therapeutics Inc

4.02B

CVI

CVR Energy Inc

3.29B

create a stock picker with 1000 to spend

Intellectia · 44 candidates

Market Cap: 1000.00M - 15.00BPrice: $10.00 - $40.00Rsi Category: moderateList Exchange: XNYS, XNAS, XASEMonth Price Change Pct: $10.00 - $35.00One Week Rise Prob: 0 - 100Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

BTU

Peabody Energy Corp

4.65B

PLSE

Pulse Biosciences Inc

1.45B

PUMP

ProPetro Holding Corp

1.81B

TEN

Tsakos Energy Navigation Ltd

1.19B

CRK

Comstock Resources Inc

6.27B

VECO

Veeco Instruments Inc

2.08B

strong short term stocks

Intellectia · 19 candidates

Market Cap: >= 5.00BRsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $3.00Month Price Change Pct: >= $10.00

Ticker

Name

Market Cap$

CZR

Caesars Entertainment Inc

5.71B

HIMS

Hims & Hers Health Inc

5.65B

DELL

Dell Technologies Inc

100.48B

PBF

PBF Energy Inc

5.09B

CGON

CG Oncology Inc

5.43B

TERN

Terns Pharmaceuticals Inc

5.06B

Whales Holding HIMS

Farallon Capital Management, L.L.C.

The State of Michigan Retirement Systems

Trading Trends

People Also Watch

Frequently Asked Questions

What is Hims & Hers Health Inc (HIMS) stock price today?

The current price of HIMS is 36.17 USD — it has decreased -5.51

What is Hims & Hers Health Inc (HIMS)'s business?

What is the price predicton of HIMS Stock?

Wall Street analysts forecast HIMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIMS is32.95 USD with a low forecast of 16.50 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.